Co-Head of Life Sciences, China
Ting is a Partner in the IPT practice of DLA Piper's Shanghai office. She also co-leads the firm’s Life Sciences practice in China. Her practice focuses on patents, trade secrets and other technology-related matters. She specializes in licensing and technology transfer, life sciences and healthcare related regulatory work, and also handles IP enforcement and litigation matters.
Prior to her legal career, Ting worked as a research scientist in the National Key Laboratory of Chinese Academy of Sciences and a renowned research institute in Canada. Ting leverages her advanced scientific research background and deep understanding of client’s technical field to routinely advise clients from a wide variety of emerging and innovative sectors, including life sciences and healthcare, chemical, automotive, information technology, artificial intelligence and new energy.
- Representing one of the largest Chinese pharmaceutical CDMOs/CROs in multiple cross-border transactions, including an in-license of DNA library screening technology from a top U.S. university, a joint development and collaboration agreement with a U.S. supplier of API compounds, and multiple outbound service agreements.
- Advising a large Vietnamese conglomerate on a complex technology and IP in-licensing, component supply and services transaction with a Chinese state-owned automobile manufacturer involving the Chinese automobile OEM’s electrical and electronic (E/E) architecture.
- Representing an Irish company in a distribution arrangement with one of the largest pharmaceutical conglomerate in China relating to a novel drug.
- Acting for a major U.S. lithium battery company in negotiating and drafting a joint development and manufacturing agreement with a Central State Owned Enterprise for the manufacture of ultrahigh capacitor batteries in China for use in the public transport road and rail infrastructure.
- Advising a major Chinese OEM of electronic devices in a legal action brought by its licensor in U.S. concerning disputes on royalty payment and trademark infringement.
- Advising a U.S. application-delivery-networking-technology company on complex transaction with Chinese partner to have networking equipment “made in China” and distributed in China, including preparing manufacturing and IP license agreement as well as component supply agreement.
- Advising a German banking IT system provider on complex licensing, back licensing and technology transfer issues in connection with its joint venture arrangement with a Chinese state-owned enterprise.
- Advising a major American manufacturer of diagnostic healthcare products on various NMPA regulatory and compliance issues concerning its China entry.
- Advising a leading Chinese high-tech company on the U.S. Export Administration Regulations (EAR) and sanctions.
- Chinese (Mandarin)
- University of Toronto, Juris Doctor
- University of Toronto, Master of Science
- Wuhan University, Bachelor of Science (Ranked 2nd out of 210)
- Ting has been recognized by Legal 500 Asia Pacific as "Next Generation Partner” for China Life Sciences and Healthcare practice for year 2022/2023.
- Ting has been recognized as “Notable Practitioner” by Managing Intellectual Property 2022.
My latest insights
DLA Piper advises Xeltis on strategic cooperation with Grand Pharma
21 September 2022 .2 minute read
DLA Piper attends signing ceremony for exclusive strategic collaboration with Beijing...
28 August 2022 .2 minute read